Literature DB >> 18007551

Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions.

Ajay Duseja1, Ashim Das, Radha Krishan Dhiman, Yogesh Kumar Chawla, Kiran T Thumburu, Sanjay Bhadada, Anil Bhansali.   

Abstract

BACKGROUND: Insulin resistance plays an important role in the pathogenesis of NAFLD. Pharmacological treatment of patients with NAFLD is still evolving. Insulin sensitizing drugs like metformin may be effective in these patients. Twenty five adult patients with NAFLD who did not achieve normalization of alanine transaminases (ALT) after 6 months of lifestyle interventions and UDCA were treated with metformin 500mg tid for 6 months. Insulin resistance was determined by HOMA- IR. Liver function tests were done monthly and patients were defined having no response, partial response or complete biochemical response depending on the change in ALT. Results were compared with 25 patients with NAFLD from the same cohort treated only with lifestyle interventions (disease controls).
RESULTS: Thirteen (52%) patients had class III (n = 5) or class IV (n = 8) disease amounting to histological NASH. Of these 13 patients none had severe inflammation and none had stage 4 fibrosis (cirrhosis). All 25 patients with NAFLD had insulin resistance in comparison to healthy controls. In comparison to disease controls (127.5 +/- 41.8 vs. 118 +/- 21.6 p = NS), all patients treated with metformin had partial biochemical response (mean ALT 122.2 +/- 26.8 vs 74.3 +/- 4.2 p < 0.01) and 14 (56%) of them achieved complete normalization of ALT.
CONCLUSIONS: Metformin is effective to achieve biochemical response in patients with NAFLD who do not respond to lifestyle interventions and UDCA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18007551

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  23 in total

1.  Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome.

Authors:  Mira Aubuchon; Allen R Kunselman; William D Schlaff; Michael P Diamond; Christos Coutifaris; Sandra A Carson; Michael P Steinkampf; Bruce R Carr; Peter G McGovern; Nicholas A Cataldo; Gabriella G Gosman; John E Nestler; Evan R Myers; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

2.  Treatment options for nonalcoholic Fatty liver disease.

Authors:  Shivakumar Chitturi
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

Review 3.  Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.

Authors:  Ajay Duseja; Shivaram P Singh; Vivek A Saraswat; Subrat K Acharya; Yogesh K Chawla; Subhankar Chowdhury; Radha K Dhiman; Rohinivilasam V Jayakumar; Kaushal Madan; Sri P Misra; Hrudananda Mishra; Sunil K Modi; Arumugam Muruganathan; Banshi Saboo; Rakesh Sahay; Rajesh Upadhyay
Journal:  J Clin Exp Hepatol       Date:  2015-03-06

4.  An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Romina Lomonaco; Janet Chen; Kenneth Cusi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

Review 5.  Nonalcoholic fatty liver disease in India - a lot done, yet more required!

Authors:  Ajay Duseja
Journal:  Indian J Gastroenterol       Date:  2010-12-30

Review 6.  Insulin sensitizers for the treatment of non-alcoholic fatty liver disease.

Authors:  Zeynel Abidin Ozturk; Abdurrahman Kadayifci
Journal:  World J Hepatol       Date:  2014-04-27

7.  Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity.

Authors:  Vsevolod Y Polotsky; Susheel P Patil; Vladimir Savransky; Alison Laffan; Shannon Fonti; Leigh A Frame; Kimberly E Steele; Michael A Schweizter; Jeanne M Clark; Michael S Torbenson; Alan R Schwartz
Journal:  Am J Respir Crit Care Med       Date:  2008-10-31       Impact factor: 21.405

Review 8.  Molecular mechanisms involved in NAFLD progression.

Authors:  Mariano Malaguarnera; Michelino Di Rosa; Ferdinando Nicoletti; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2009-04-08       Impact factor: 4.599

Review 9.  Hypertension and hepatic steatosis.

Authors:  Matthew J Brookes; Tariq H Iqbal; Brian T Cooper
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

Review 10.  Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.

Authors:  Lance L Stein; Mamie H Dong; Rohit Loomba
Journal:  Adv Ther       Date:  2009-11-16       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.